Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Awaken prone positioning (APP) ventilation has been widely accepted as a standard regimen in the management of COVID-19 patients. Physiological studies have proved ventilation/perfusion improvement during APP in COVID-19, which was associated improved oxygenation. However, the optimal duration for APP was not yet demonstrated. In this study, we aimed at the prolonged APP to see whether this could improve patients outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| APP group | Experimental | Directive APP for a target of 12 hours per day or more |
|
| Control group | No Intervention | No intervention on APP |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Awaken prone positioning ventilation | Procedure | patients were mandated to keep a prone position for at least 12 hours. |
|
| Measure | Description | Time Frame |
|---|---|---|
| 28-day intubation rate | whether the patients' were intubated | follow-up till 28-day |
| Measure | Description | Time Frame |
|---|---|---|
| APP duration/days | hours of APP per day | follow-up till APP ended, daily duration of APP also recoreded, up to 7 days |
| Application of HFNC NIV vasopressor CRRT ECMO sedation, or complication | Whether to apply these treatments，any complications occur,days free from respiratory support and days free from invasive mechanical ventilation at 28 day |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events of interest | All adverse events of interest that occur in both randomised arms will be reported up to day 28 post-randomisation, including the following:
| 28 post-randomisation |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Haibo QIU, Dr | Southeast University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Southeast University | Nanjing | Jiangsu | 210009 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40549277 | Derived | Sun Q, Zhang R, Zhang J, Xie J, Huang Y, Yang Y, Qiu H, Liu L, Chen H; Chi-ARDS Net (Chinese ARDS Research Network). Impact of awake prone positioning duration on intubation or mortality in COVID-19 patients with acute respiratory failure: secondary analysis of a randomized clinical trial. Ann Intensive Care. 2025 Jun 23;15(1):84. doi: 10.1186/s13613-025-01501-8. | |
| 39088076 |
Not provided
Not provided
from the email：liulingdoctor@126.com
Not provided
Starting from the official publication of the manuscript to 1 year later
collaborator
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| follow-up till 28-day |
| mortality (ICU hospital) length of ICU (hospital) stay | mortality AND mortality and length of stay at 28 day | follow-up during the ICU/hospital stay, up to 28 days |
| Liu L, Sun Q, Zhao H, Liu W, Pu X, Han J, Yu J, Jin J, Chao Y, Wang S, Liu Y, Wu B, Zhu Y, Li Y, Chang W, Chen T, Xie J, Yang Y, Qiu H, Slutsky A; Chi-ARDS Net (Chinese ARDS Research Network). Prolonged vs shorter awake prone positioning for COVID-19 patients with acute respiratory failure: a multicenter, randomised controlled trial. Intensive Care Med. 2024 Aug;50(8):1298-1309. doi: 10.1007/s00134-024-07545-x. Epub 2024 Aug 1. |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |